Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOST | Q9BQB4 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 6/20 | 0.31 |
| ▸ | NPC1 | O15118 | 5/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3231502 | 0.82 | CHRNB2 (0.39) | SOSTPOLBCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL17032812 | 0.81 | CHRNB2 (0.38) | SOSTCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL25010722 | 0.78 | CHRNB2 (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3RAB9A | |
| SCHEMBL17037033 | 0.78 | CHRNB2 (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3RAB9A | |
| SCHEMBL17038774 | 0.77 | TSHR (0.48) | CHRNB2CHRNA4CHRNB4CHRNA3RAB9A | |
| SCHEMBL17057328 | 0.75 | RAB9A (0.33) | CHRNB2CHRNA4CHRNB4CHRNA3RAB9A | |
| SCHEMBL5501263 | 0.75 | RAB9A (0.33) | CHRNB2CHRNA4CHRNB4CHRNA3RAB9A | |
| SCHEMBL18312023 | 0.75 | RAB9A (0.33) | CHRNB2CHRNA4CHRNB4CHRNA3RAB9A | |
| SCHEMBL22553973 | 0.74 | RAB9A (0.35) | CHRNB2CHRNA4RAB9ANPC1KMT2A | |
| SCHEMBL29974600 | 0.74 | POLB (0.50) | POLBCHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117203202-A | Quinoxaline derivative and use thereof | 黑钻治疗公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20170226142-A1 | Factor D Inhibitors Useful for Treating Inflammatory Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-9643986-B2 | Factor D inhibitors useful for treating inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160362399-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362398-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362433-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20150239837-A1 | Factor D Inhibitors Useful for Treating Inflammatory Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362433-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, C9, TFPI | SOST 3987/4885POLB 4107/4885CHRNB2 4297/4885 |
| US-20160362398-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, CFH | SOST 3361/4885POLB 3554/4885CHRNB2 4473/4885 |
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, CFH, TFPI | SOST 1965/4885POLB 1498/4885CHRNB2 4215/4885 |
| US-20150239837-A1 | Factor D Inhibitors Useful for Treating Inflammatory Disorders | CFD, TFPI, TFPI2 | SOST 3530/4885POLB 3781/4885CHRNB2 3766/4885 |
| US-20170226142-A1 | Factor D Inhibitors Useful for Treating Inflammatory Disorders | CFD, TFPI, TFPI2 | SOST 3530/4885POLB 3781/4885CHRNB2 3766/4885 |
| US-20160362399-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, CFH, TFPI | SOST 3788/4885POLB 3762/4885CHRNB2 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.